Coherus Oncology, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersRedwood City, CA
SAM.gov UEIV13JDMAMELK8
Coherus Oncology develops immuno-oncology therapies for cancer treatment. The company's product portfolio includes toripalimab-tpzi (PD-1), an FDA-approved anti-PD-1 monoclonal antibody marketed as LOQTORZI for treating recurrent, locally advanced or metastatic nasopharyngeal carcinoma, along with pipeline candidates tagmokitug (CCR8) and casdozokitug (IL-27). The company focuses on combination therapies designed to address immune resistance in cancer.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Coherus Oncology, INC. | Redwood City | CA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.